{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:13:56Z","timestamp":1793121236894,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bpg.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:40:26Z","timestamp":1528936826000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Improving prognosis in primary biliary cholangitis \u2013 Therapeutic options and strategy"],"prefix":"10.1016","volume":"34-35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-3286","authenticated-orcid":false,"given":"Maren H.","family":"Harms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk R.","family":"van Buuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0016-5085(77)80012-7","article-title":"Effect of D-penicillamine on copper retention in patients with primary billiary cirrhosis","volume":"72","author":"Deering","year":"1977","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM198202113060602","article-title":"A\u00a0prospective trial of D-penicillamine in primary biliary cirrhosis","volume":"306","author":"Matloff","year":"1982","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/gut.26.2.114","article-title":"Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis","volume":"26","author":"Neuberger","year":"1985","journal-title":"Gut"},{"issue":"2-3","key":"10.1016\/j.bpg.2018.06.004_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis","volume":"48","author":"Floreani","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.bpg.2018.06.004_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: a comprehensive review","volume":"64","author":"Webb","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0168-8278(02)00440-3","article-title":"Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis","volume":"38","author":"Invernizzi","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1440-1746.1991.tb00911.x","article-title":"Primary biliary cirrhosis: is there an environmental contribution?","volume":"6","author":"Triger","year":"1991","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0168-8278(94)80255-6","article-title":"Antibodies to atypical mycobacteria in primary biliary cirrhosis","volume":"21","author":"O'Donohue","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/jhep.2001.21165","article-title":"Risk factors for primary biliary cirrhosis in a cohort of patients from the United States","volume":"33","author":"Parikh-Patel","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address eee, European Association for the Study of the Liver, EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib13","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2009.12.002","article-title":"The new therapeutic frontier\u2013nuclear receptors and the liver","volume":"52","author":"Karpen","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib15","doi-asserted-by":"crossref","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.004_bib17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MEG.0b013e328353753d","article-title":"The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study","volume":"24","author":"Baldursdottir","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib18","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib19","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.23210","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study","volume":"50","author":"Myers","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2018.06.004_bib20","doi-asserted-by":"crossref","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/0016-5085(90)91091-J","article-title":"Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study","volume":"98","author":"Balasubramaniam","year":"1990","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib25","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib26","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/MEG.0b013e328320005f","article-title":"Variceal bleeding in primary biliary cirrhosis patients: a subgroup with improved prognosis and a model to predict survival after first bleeding","volume":"21","author":"Vlachogiannakos","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.004_bib29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/00365520510023215","article-title":"Survival following the development of ascites and\/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model","volume":"40","author":"Chan","year":"2005","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0168-8278(05)80139-4","article-title":"Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years","volume":"20","author":"Mahl","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.2003.023937","article-title":"Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort","volume":"53","author":"Prince","year":"2004","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis","volume":"94","author":"Springer","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.004_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF01308413","article-title":"Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study","volume":"30","author":"Leuschner","year":"1985","journal-title":"Dig Dis Sci"},{"issue":"19","key":"10.1016\/j.bpg.2018.06.004_bib35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.bpg.2018.06.004_bib36","first-page":"2314","article-title":"Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis","volume":"91","author":"Batts","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib37","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression","volume":"29","author":"Degott","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Pares","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2015","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib42","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.004_bib44","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib45","first-page":"759","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib46","first-page":"1148","article-title":"Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?","volume":"23","author":"Kilmurry","year":"1996","journal-title":"Hepatology"},{"issue":"9184","key":"10.1016\/j.bpg.2018.06.004_bib47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.004_bib48","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2018.06.004_bib49","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2018.06.004_bib50","article-title":"Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis","volume":"3","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib51","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.510290140","article-title":"Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis","volume":"29","author":"Bonnand","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib55","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib56","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.004_bib57","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib58","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib59","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.004_bib60","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2018.06.004_bib61","series-title":"Poster presented at the 68th american association for the study of liver disease liver meeting","article-title":"Ursodeoxycholic acid is associated with a prolonged transplant-free survival in all patients with primary biliary cholangitis \u2013 there is no such thing as non-response","author":"Van der Meer","year":"2017"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib62","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"13","key":"10.1016\/j.bpg.2018.06.004_bib63","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian inflammatory bowel disease study group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Guanabens","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib65","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib67","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.004_bib69","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0026-0495(93)90056-T","article-title":"The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities","volume":"42","author":"Day","year":"1993","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.bpg.2018.06.004_bib70","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","article-title":"Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"49","author":"Walker","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2018.06.004_bib73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib75","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","author":"Han","year":"2012","journal-title":"J.\u00a0Dig. Dis."},{"issue":"10","key":"10.1016\/j.bpg.2018.06.004_bib76","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","article-title":"Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score","volume":"61","author":"Hegade","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib78","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.004_bib79","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","author":"Kurihara","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2018.06.004_bib80","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00535-004-1518-3","article-title":"Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis","volume":"40","author":"Akbar","year":"2005","journal-title":"J\u00a0Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2018.06.004_bib82","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels","volume":"41","author":"Kita","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib84","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A\u00a02-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) [abstract]","volume":"66","author":"Corpechot","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2018.06.004_bib89","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.bpg.2018.06.004_bib90","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib91","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib92","doi-asserted-by":"crossref","first-page":"500","DOI":"10.7326\/0003-4819-99-4-500","article-title":"NIH conference: primary biliary cirrhosis: a model autoimmune disease","volume":"99","author":"James","year":"1983","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib93","article-title":"Azathioprine for primary biliary cirrhosis","author":"Gong","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib94","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib95","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0168-8278(94)80092-8","article-title":"Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study","volume":"21","author":"McCormick","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.bpg.2018.06.004_bib96","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1046\/j.1365-2036.2000.00869.x","article-title":"Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis","volume":"14","author":"Almasio","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib97","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","article-title":"Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis","volume":"25","author":"Leuschner","year":"1996","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2018.06.004_bib98","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.1840100405","article-title":"A\u00a0pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss","volume":"10","author":"Mitchison","year":"1989","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib99","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J\u00a0Hepatol"},{"issue":"20","key":"10.1016\/j.bpg.2018.06.004_bib100","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A\u00a0controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","author":"Wiesner","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib101","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0168-8278(05)80043-1","article-title":"The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group","volume":"17","year":"1993","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.004_bib102","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.mcg.0000177235.36640.21","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Treiber","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib103","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3748\/wjg.v22.i1.349","article-title":"Combination antiretroviral studies for patients with primary biliary cirrhosis","volume":"22","author":"Lytvyak","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2018.06.004_bib104","author":"European Association for the Study of the Liver ELTR overall indications and results"},{"key":"10.1016\/j.bpg.2018.06.004_bib105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-230X-10-144","article-title":"Trends in liver transplantation for primary biliary cirrhosis in The Netherlands 1988-2008","volume":"10","author":"Kuiper","year":"2010","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2018.06.004_bib106","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/tri.12877","article-title":"Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation","volume":"30","author":"Singal","year":"2017","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib107","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the european liver transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2018.06.004_bib108","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s11605-010-1256-1","article-title":"Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases\u2013an analysis of the UNOS database","volume":"14","author":"Kashyap","year":"2010","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"2","key":"10.1016\/j.bpg.2018.06.004_bib109","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bpg.2017.04.004","article-title":"Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation","volume":"31","author":"Visseren","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2018.06.004_bib110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0035-1571273","article-title":"Primary biliary cirrhosis beyond ursodeoxycholic acid","volume":"36","author":"Corpechot","year":"2016","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.bpg.2018.06.004_bib111","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691818300192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691818300192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:01:45Z","timestamp":1761498105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691818300192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":111,"alternative-id":["S1521691818300192"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2018.06.004","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving prognosis in primary biliary cholangitis \u2013 Therapeutic options and strategy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}